GDMH join forces with biotechnology company Ascelia Pharma for patient identification processes in the SPARKLE study
GDMH join forces with Biotechnology Company Ascelia Pharma, which envisions the co-creation and co-development activities on the SPARKLE study held at Fondazione Policlinico Universitario A. Gemelli IRCCS. Ascelia Pharma, a biotech focused on improving the life of people living with rare cancer conditions is conducting the pivotal Phase 3 clinical studySPARKLE with the candidate drug Orviglance, […]




